News & Events

Lipoprotein (a) and CVD - What Therapeutic Options?

Gilles Lambert is Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a group leader at Inserm UMR1188 DéTROI laboratory.

Prof Lambert was awarded a PhD in Pathophysiology from the University of Paris in 1998. He specialized in lipidology, first as a post-doctoral fellow at the Molecular Disease Branch of the National Institutes of Health (Bethesda MD, USA) under the supervision of Dr. H Bryan Brewer Jr. and as a senior research fellow at the Heart Research Institute (Sydney NSW, Australia) in the lipid research group led by Prof Philip Barter.

In recent years, Prof Lambert has conducted seminal research projects on PCSK9, a protein that targets the LDL receptor for intracellular degradation, and as such, the target of novel cholesterol lowering therapies: the PCSK9 inhibitors. He has received several competitive research grants in Australia and in France to study the cardiovascular benefits and potential side effects of PCSK9 inhibition.

Prof Lambert’s current research interests are to elucidate the specific role of PCSK9 in insulin producing beta-cells and to understand the cellular pathways by which PCSK9 modulates the circulating levels of lipoprotein (a), a highly atherogenic lipoprotein species.

All welcome

Enquiries: Blake Cochran

File Attachment: 
Event Date: 
Thursday, 22 November 2018 - 1:00pm
Wallace Wurth LG02
Open to: 
Booking deadline: